Gemcitabine
About
Therapy type: Chemotherapy
Therapy strategy: Antimetabolite
Mappings
NCI Thesaurus: Gemcitabine (ncit:C66876)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Durvalumab, Gemcitabine, Tremelimumab | |
| Sensitivity (+) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Durvalumab, Gemcitabine, Tremelimumab | |
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Gemcitabine, Margetuximab | |
| Sensitivity (+) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Gemcitabine, Nivolumab | |
| Sensitivity (+) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Carboplatin, Gemcitabine, Pembrolizumab | |
| Sensitivity (+) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Durvalumab, Gemcitabine, Tremelimumab | |
| Sensitivity (+) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Durvalumab, Gemcitabine, Tremelimumab | |
| Sensitivity (+) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Durvalumab, Gemcitabine |